Detalles de la búsqueda
1.
A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events.
N Engl J Med
; 374(7): 625-35, 2016 Feb 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-26644172
2.
Successful utilization of an electronic pain diary in a multinational phase 3 interventional study of pediatric sickle cell anemia.
Clin Trials
; 14(6): 563-571, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-28743191
3.
Design of the DOVE (Determining Effects of Platelet Inhibition on Vaso-Occlusive Events) trial: A global Phase 3 double-blind, randomized, placebo-controlled, multicenter study of the efficacy and safety of prasugrel in pediatric patients with sickle cell anemia utilizing a dose titration strategy.
Pediatr Blood Cancer
; 63(2): 299-305, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26402148
4.
Novel findings from the multinational DOVE study on geographic and age-related differences in pain perception and analgesic usage in children with sickle cell anaemia.
Br J Haematol
; 184(6): 1058-1061, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29676449
5.
A prospective randomized trial comparing the recovery of platelet function after loading dose administration of prasugrel or clopidogrel.
Platelets
; 24(1): 15-25, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-22372531
6.
Geographic Differences in Phenotype and Treatment of Children with Sickle Cell Anemia from the Multinational DOVE Study.
J Clin Med
; 8(11)2019 Nov 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-31744266
7.
Clinical trial conduct in special populations and developing regions: An overview of the DOVE study in pediatric patients with sickle cell disease.
Contemp Clin Trials
; 64: 88-94, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29104118
8.
Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemia.
Thromb Haemost
; 117(3): 580-588, 2017 02 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-27929203
9.
The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: a retrospective analysis of the FEATHER study.
Thromb Res
; 134(3): 552-7, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25022828
10.
Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease.
Thromb Haemost
; 111(5): 943-50, 2014 May 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-24402637
11.
Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients.
J Am Coll Cardiol
; 62(7): 577-83, 2013 Aug 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-23747759
12.
Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial.
J Am Coll Cardiol
; 60(20): 2032-40, 2012 Nov 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-23083774
13.
Protist genetic diversity in the acidic hydrothermal environments of Lassen Volcanic National Park, USA.
J Eukaryot Microbiol
; 53(6): 420-31, 2006.
Artículo
en Inglés
| MEDLINE | ID: mdl-17123405
Resultados
1 -
13
de 13
1
Próxima >
>>